カテゴリー： Allied Market Research, 世界, 医療/バイオ

抗菌薬耐性のグローバル市場（2023-2032）：併用療法、テトラサイクリン系薬剤、セファロスポリン系薬剤、糖ペプチド・脂肪糖ペプチド、オキサゾリジノン系薬剤、その他

◆英語タイトル：Antimicrobial Resistance Market By Drug Class (Combination therapies, Tetracyclines, Cephalosporins, Glycopeptides and Lipoglycopeptides, Oxazolidinones, Others), By Pathogen (Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus Spp, Others), By Indication (Complicated Urinary Tract Infections (cUTI), Blood stream infections, Acute bacterial skin and skin structure infections (ABSSSI), Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP), Community acquired pneumonia (CAP), Others), By Mechanism of Action (Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Allied Market Researchが発行した調査報告書（ALD23OCT116）◆商品コード：ALD23OCT116
◆発行会社（リサーチ会社）：Allied Market Research
◆発行日：2023年8月
◆ページ数：389
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

抗菌薬耐性市場は2022年に46億ドルと評価され、2023年から2032年までの年平均成長率は7.6%で、2032年には95億ドルに達すると予測されています。抗菌薬耐性（AMR）とは、薬剤耐性とも呼ばれ、細菌、ウイルス、真菌、寄生虫が一定期間内に利用可能な抗菌薬に対して発現する耐性のことです。これは包括的な概念であり、多くの場合、抗菌薬、抗ウイルス薬、抗寄生虫薬、抗真菌薬に対する耐性を含みます。ほとんどの抗菌薬に耐性を持つようになった微生物は、しばしばスーパーバグと呼ばれます。スーパーバグの例としては、MRSA（メチシリン耐性黄色ブドウ球菌）、クロストリジウム・ディフィシル（C. difficile）、多剤耐性結核菌などが挙げられます。
抗菌薬に対する耐性は、微生物が生殖周期の間に起こす遺伝的変化によって、時間の経過とともに発達することがよくあります。DNAの変化により、抗菌薬が微生物の細胞に到達するのを妨げるバリアが形成されたり、抗菌薬の効果を打ち消す酵素を作り出す能力が発達したりします。
抗菌薬耐性は、抗生物質の過剰使用に大きく影響されます。抗菌薬に対する耐性は、抗生物質の過剰使用に大きく影響されます。抗生物質の治療期間が短すぎたり、効果が弱かったり、特定の感染症に対して不適切であったりすると、回復力のある微生物が残ってしまう可能性が高くなります。さらに、風邪やインフルエンザなどのウイルス感染症や、抗生物質が効かない軽い病気に対して、不必要に抗生物質が処方されることもよくあります。過剰処方は、細菌を不必要に抗生物質にさらすことになり、耐性菌のリスクを高めます。

さらに、微生物が抗菌薬に繰り返しさらされたり、すでに耐性を持つ他の微生物と接触したりすることで、耐性菌が発生・蔓延する機会が多くなります。したがって、抗菌薬を適切に使用し、抗菌薬耐性のリスクを最小限に抑えることが極めて重要です。
さらに、この抗菌薬耐性と戦うための政府のイニシアチブの増加は、抗菌薬耐性市場の成長を後押しする主な要因です。例えば、世界抗菌薬耐性研究開発（AMR R&D）ハブは、政府、非政府ドナー組織、政府間組織による協力体制であり、ワンヘルス戦略を用いて困難を解決し、世界的なAMR R&Dにおける協調と協力を強化しています。

一方、これらの新規治療薬のコストが高いことが、市場成長の阻害要因になると予想されています。これらの抗菌薬候補の研究開発には多額の費用がかかるため、製品のコストが高くなります。このため、低所得国の人々が高コストの先進的抗菌薬を購入し、抗菌薬耐性を回避することは難しく、市場成長の妨げになる可能性があります。
しかし、抗菌薬耐性と闘うための抗生物質治療薬のパイプラインは充実しており、予測期間中の市場成長に有利な機会を提供すると期待されます。研究者や製薬企業は、抗菌薬耐性と闘うための革新的な治療法や治療法を開発し、新たな治療オプションの可能性を提供しています。さらに、革新的な抗生物質の開発は、医療従事者に幅広い治療選択肢を提供します。異なる作用機序を持つ複数の有効な抗生物質があれば、高度耐性菌による感染症であっても、治療に成功する可能性が高まります。これにより、抗菌薬耐性の脅威を効果的に克服し、予測期間中の市場成長に貢献することが期待されます。
抗菌薬耐性市場は、薬剤クラス、病原体、適応症、作用機序、地域によって区分されます。薬剤クラスベースでは、併用療法、テトラサイクリン系薬剤、セファロスポリン系薬剤、グリコペプチド・リポグリコペプチド系薬剤、オキサゾリジノン系薬剤、その他に分類されます。病原体別では、市場は大腸菌、肺炎桿菌、緑膿菌、黄色ブドウ球菌、腸球菌、その他に区分されます。

疾患タイプ別では、市場は複雑性尿路感染症（cUTI）、血流感染症、急性細菌性皮膚・皮膚構造感染症（ABSSSI）、院内獲得細菌性肺炎および人工呼吸器獲得細菌性肺炎（HABPおよびVABP）、市中獲得肺炎（CAP）、その他に細分化されます。作用機序別では、市場はタンパク質合成阻害剤、細胞壁合成阻害剤、その他に分類されます。地域別では、北米（アメリカ、カナダ、メキシコ）、ヨーロッパ（ドイツ、フランス、イギリス、イタリア、スペイン、ヨーロッパのその他地域）、アジア太平洋（中国、日本、オーストラリア、インド、韓国、アジア太平洋のその他地域）、中南米・中東・アフリカ（ブラジル、南アフリカ、サウジアラビア、中南米・中東・アフリカのその他地域）で分析されます。

世界の抗菌薬耐性市場で事業を展開する主な主要企業は、Alkem Laboratories Ltd、Innoviva, Inc.、Pfizer Inc.、Merck & Co., Inc.、Acurx Pharmaceuticals, Inc.、Basilea Pharmaceutica Ltd.、Cumberland Pharmaceuticals Inc.、Wockhardt Limited、Paratek Pharmaceuticals, Inc.、Nabriva Therapeutics plc.です。

ステークホルダーにとっての主なメリット
本レポートは、2022年から2032年までの抗菌薬耐性市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、一般的な抗菌薬耐性市場の機会を特定します。
市場調査は、主要な促進要因、阻害要因、機会に関する情報とともに提供されます。
ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
抗菌剤耐性市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
地域別および世界別の抗菌剤耐性市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

本レポートをご購入いただくと、以下の特典があります：
四半期ごとの更新可能です*（コーポレート・ライセンスの場合のみ、表示価格でのご提供となります）
無料のアップデートとして、購入前または購入後に、5社の会社概要を追加可能です。
アナリストによる16時間のサポート可能です。* (購入後、レポートのレビューで追加のデータ要件が見つかった場合、質問や販売後の問い合わせを解決するためにアナリストによる16時間のサポートを受けることができます)
15% の無料カスタマイズ可能です。* （レポートの範囲またはセグメントが要件と一致しない場合、20% は 3 営業日の無料作業に相当し、1 回適用されます。）
5ユーザー・エンタープライズユーザーライセンスの無料データパック可能です。(Excel版レポート）
レポートが6～12ヶ月以上前の場合、無料更新可能です。
24時間優先対応可能です。
産業の最新情報とホワイトペーパーを無料で提供します。

本レポートで可能なカスタマイズ（追加費用とスケジュールが必要です。）
規制ガイドライン
クライアントの関心に特化した追加企業プロファイル
国または地域の追加分析-市場規模と予測
企業プロファイルの拡張リスト
過去の市場データ

主要市場セグメント

適応症別
合併症性尿路感染症（cUTI）
血流感染症
急性細菌性皮膚・皮膚構造感染症（ABSSSI）
院内獲得細菌性肺炎および人工呼吸器獲得細菌性肺炎（HABPおよびVABP）
市中肺炎（CAP）
その他

薬剤クラス別
併用療法
テトラサイクリン系抗菌薬
セファロスポリン
糖ペプチドおよび脂肪糖ペプチド
オキサゾリジノン系
その他

作用機序別
タンパク質合成阻害剤
細胞壁合成阻害剤
その他

病原体別
肺炎桿菌
緑膿菌
黄色ブドウ球菌
腸球菌
その他
大腸菌

地域別
北米
アメリカ
カナダ
メキシコ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
アジア太平洋
日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域
中南米・中東・アフリカ
ブラジル
サウジアラビア
南アフリカ
その他の地域

主要市場プレイヤー
Pfizer Inc.
Cumberland Pharmaceuticals
Acurx Pharmaceuticals, Inc.
Paratek Pharmaceuticals Inc
Alkem Laboratories Ltd.
Nabriva Therapeutics plc
Innoviva, Inc
Basilea Pharmaceutica Ltd
Wockhardt Limited.
Merck & Co., Inc.

第1章. 序章
第2章. エグゼクティブサマリー
第3章. 市場概要
第4章. 抗菌薬耐性の市場分析：薬物クラス別
第5章. 抗菌薬耐性の市場分析：病原菌別
第6章. 抗菌薬耐性の市場分析：疾患別
第7章. 抗菌薬耐性の市場分析：作用機序別
第8章. 抗菌薬耐性の市場分析：地域別
第9章. 競争状況
第10章. 企業情報

❖ レポートの目次 ❖

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Overuse and misuse of antibiotics
3.4.1.2. Rise in prevalence of antimicrobial resistance bacterial infections
3.4.1.3. Growth in burden of antimicrobial resistance

3.4.2. Restraints
3.4.2.1. Global shortage of innovative antibiotics to combat antimicrobial resistance

3.4.3. Opportunities
3.4.3.1. Surge in initiative to tackle antimicrobial resistance (AMR) globally

CHAPTER 4: ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Combination therapies
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Tetracyclines
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Cephalosporins
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Glycopeptides and Lipoglycopeptides
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Oxazolidinones
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
4.7. Others
4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market share analysis by country
CHAPTER 5: ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN
5.1. Overview
5.1.1. Market size and forecast
5.2. Escherichia coli
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Klebsiella pneumoniae
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Pseudomonas aeruginosa
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Staphylococcus aureus
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Enterococcus Spp
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
5.7. Others
5.7.1. Key market trends, growth factors and opportunities
5.7.2. Market size and forecast, by region
5.7.3. Market share analysis by country
CHAPTER 6: ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Complicated Urinary Tract Infections (cUTI)
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Blood stream infections
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Acute bacterial skin and skin structure infections (ABSSSI)
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP)
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
6.6. Community acquired pneumonia (CAP)
6.6.1. Key market trends, growth factors and opportunities
6.6.2. Market size and forecast, by region
6.6.3. Market share analysis by country
6.7. Others
6.7.1. Key market trends, growth factors and opportunities
6.7.2. Market size and forecast, by region
6.7.3. Market share analysis by country
CHAPTER 7: ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION
7.1. Overview
7.1.1. Market size and forecast
7.2. Protein Synthesis Inhibitors
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Cell Wall Synthesis Inhibitors
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Others
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: ANTIMICROBIAL RESISTANCE MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by Drug Class
8.2.3. Market size and forecast, by Pathogen
8.2.4. Market size and forecast, by Indication
8.2.5. Market size and forecast, by Mechanism of Action
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by Drug Class
8.2.6.1.2. Market size and forecast, by Pathogen
8.2.6.1.3. Market size and forecast, by Indication
8.2.6.1.4. Market size and forecast, by Mechanism of Action
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by Drug Class
8.2.6.2.2. Market size and forecast, by Pathogen
8.2.6.2.3. Market size and forecast, by Indication
8.2.6.2.4. Market size and forecast, by Mechanism of Action
8.2.6.3. Mexico
8.2.6.3.1. Market size and forecast, by Drug Class
8.2.6.3.2. Market size and forecast, by Pathogen
8.2.6.3.3. Market size and forecast, by Indication
8.2.6.3.4. Market size and forecast, by Mechanism of Action
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by Drug Class
8.3.3. Market size and forecast, by Pathogen
8.3.4. Market size and forecast, by Indication
8.3.5. Market size and forecast, by Mechanism of Action
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by Drug Class
8.3.6.1.2. Market size and forecast, by Pathogen
8.3.6.1.3. Market size and forecast, by Indication
8.3.6.1.4. Market size and forecast, by Mechanism of Action
8.3.6.2. France
8.3.6.2.1. Market size and forecast, by Drug Class
8.3.6.2.2. Market size and forecast, by Pathogen
8.3.6.2.3. Market size and forecast, by Indication
8.3.6.2.4. Market size and forecast, by Mechanism of Action
8.3.6.3. UK
8.3.6.3.1. Market size and forecast, by Drug Class
8.3.6.3.2. Market size and forecast, by Pathogen
8.3.6.3.3. Market size and forecast, by Indication
8.3.6.3.4. Market size and forecast, by Mechanism of Action
8.3.6.4. Italy
8.3.6.4.1. Market size and forecast, by Drug Class
8.3.6.4.2. Market size and forecast, by Pathogen
8.3.6.4.3. Market size and forecast, by Indication
8.3.6.4.4. Market size and forecast, by Mechanism of Action
8.3.6.5. Spain
8.3.6.5.1. Market size and forecast, by Drug Class
8.3.6.5.2. Market size and forecast, by Pathogen
8.3.6.5.3. Market size and forecast, by Indication
8.3.6.5.4. Market size and forecast, by Mechanism of Action
8.3.6.6. Rest of Europe
8.3.6.6.1. Market size and forecast, by Drug Class
8.3.6.6.2. Market size and forecast, by Pathogen
8.3.6.6.3. Market size and forecast, by Indication
8.3.6.6.4. Market size and forecast, by Mechanism of Action
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by Drug Class
8.4.3. Market size and forecast, by Pathogen
8.4.4. Market size and forecast, by Indication
8.4.5. Market size and forecast, by Mechanism of Action
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Market size and forecast, by Drug Class
8.4.6.1.2. Market size and forecast, by Pathogen
8.4.6.1.3. Market size and forecast, by Indication
8.4.6.1.4. Market size and forecast, by Mechanism of Action
8.4.6.2. China
8.4.6.2.1. Market size and forecast, by Drug Class
8.4.6.2.2. Market size and forecast, by Pathogen
8.4.6.2.3. Market size and forecast, by Indication
8.4.6.2.4. Market size and forecast, by Mechanism of Action
8.4.6.3. India
8.4.6.3.1. Market size and forecast, by Drug Class
8.4.6.3.2. Market size and forecast, by Pathogen
8.4.6.3.3. Market size and forecast, by Indication
8.4.6.3.4. Market size and forecast, by Mechanism of Action
8.4.6.4. Australia
8.4.6.4.1. Market size and forecast, by Drug Class
8.4.6.4.2. Market size and forecast, by Pathogen
8.4.6.4.3. Market size and forecast, by Indication
8.4.6.4.4. Market size and forecast, by Mechanism of Action
8.4.6.5. South Korea
8.4.6.5.1. Market size and forecast, by Drug Class
8.4.6.5.2. Market size and forecast, by Pathogen
8.4.6.5.3. Market size and forecast, by Indication
8.4.6.5.4. Market size and forecast, by Mechanism of Action
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Market size and forecast, by Drug Class
8.4.6.6.2. Market size and forecast, by Pathogen
8.4.6.6.3. Market size and forecast, by Indication
8.4.6.6.4. Market size and forecast, by Mechanism of Action
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by Drug Class
8.5.3. Market size and forecast, by Pathogen
8.5.4. Market size and forecast, by Indication
8.5.5. Market size and forecast, by Mechanism of Action
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Market size and forecast, by Drug Class
8.5.6.1.2. Market size and forecast, by Pathogen
8.5.6.1.3. Market size and forecast, by Indication
8.5.6.1.4. Market size and forecast, by Mechanism of Action
8.5.6.2. Saudi Arabia
8.5.6.2.1. Market size and forecast, by Drug Class
8.5.6.2.2. Market size and forecast, by Pathogen
8.5.6.2.3. Market size and forecast, by Indication
8.5.6.2.4. Market size and forecast, by Mechanism of Action
8.5.6.3. South Africa
8.5.6.3.1. Market size and forecast, by Drug Class
8.5.6.3.2. Market size and forecast, by Pathogen
8.5.6.3.3. Market size and forecast, by Indication
8.5.6.3.4. Market size and forecast, by Mechanism of Action
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Market size and forecast, by Drug Class
8.5.6.4.2. Market size and forecast, by Pathogen
8.5.6.4.3. Market size and forecast, by Indication
8.5.6.4.4. Market size and forecast, by Mechanism of Action
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Alkem Laboratories Ltd.
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.1.7. Key strategic moves and developments
10.2. Pfizer Inc.
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. Acurx Pharmaceuticals, Inc.
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.4. Basilea Pharmaceutica Ltd
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. Cumberland Pharmaceuticals
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.5.7. Key strategic moves and developments
10.6. Wockhardt Limited.
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. Paratek Pharmaceuticals Inc
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.8. Nabriva Therapeutics plc
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.8.7. Key strategic moves and developments
10.9. Innoviva, Inc
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.10. Merck & Co., Inc.
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 02. ANTIMICROBIAL RESISTANCE MARKET FOR COMBINATION THERAPIES, BY REGION, 2022-2032 ($MILLION)
TABLE 03. ANTIMICROBIAL RESISTANCE MARKET FOR TETRACYCLINES, BY REGION, 2022-2032 ($MILLION)
TABLE 04. ANTIMICROBIAL RESISTANCE MARKET FOR CEPHALOSPORINS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. ANTIMICROBIAL RESISTANCE MARKET FOR GLYCOPEPTIDES AND LIPOGLYCOPEPTIDES, BY REGION, 2022-2032 ($MILLION)
TABLE 06. ANTIMICROBIAL RESISTANCE MARKET FOR OXAZOLIDINONES, BY REGION, 2022-2032 ($MILLION)
TABLE 07. ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. GLOBAL ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 09. ANTIMICROBIAL RESISTANCE MARKET FOR ESCHERICHIA COLI, BY REGION, 2022-2032 ($MILLION)
TABLE 10. ANTIMICROBIAL RESISTANCE MARKET FOR KLEBSIELLA PNEUMONIAE, BY REGION, 2022-2032 ($MILLION)
TABLE 11. ANTIMICROBIAL RESISTANCE MARKET FOR PSEUDOMONAS AERUGINOSA, BY REGION, 2022-2032 ($MILLION)
TABLE 12. ANTIMICROBIAL RESISTANCE MARKET FOR STAPHYLOCOCCUS AUREUS, BY REGION, 2022-2032 ($MILLION)
TABLE 13. ANTIMICROBIAL RESISTANCE MARKET FOR ENTEROCOCCUS SPP, BY REGION, 2022-2032 ($MILLION)
TABLE 14. ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 15. GLOBAL ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 16. ANTIMICROBIAL RESISTANCE MARKET FOR COMPLICATED URINARY TRACT INFECTIONS (CUTI), BY REGION, 2022-2032 ($MILLION)
TABLE 17. ANTIMICROBIAL RESISTANCE MARKET FOR BLOOD STREAM INFECTIONS, BY REGION, 2022-2032 ($MILLION)
TABLE 18. ANTIMICROBIAL RESISTANCE MARKET FOR ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI), BY REGION, 2022-2032 ($MILLION)
TABLE 19. ANTIMICROBIAL RESISTANCE MARKET FOR HOSPITAL ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR ACQUIRED BACTERIAL PNEUMONIA (HABP AND VABP), BY REGION, 2022-2032 ($MILLION)
TABLE 20. ANTIMICROBIAL RESISTANCE MARKET FOR COMMUNITY ACQUIRED PNEUMONIA (CAP), BY REGION, 2022-2032 ($MILLION)
TABLE 21. ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 22. GLOBAL ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 23. ANTIMICROBIAL RESISTANCE MARKET FOR PROTEIN SYNTHESIS INHIBITORS, BY REGION, 2022-2032 ($MILLION)
TABLE 24. ANTIMICROBIAL RESISTANCE MARKET FOR CELL WALL SYNTHESIS INHIBITORS, BY REGION, 2022-2032 ($MILLION)
TABLE 25. ANTIMICROBIAL RESISTANCE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 26. ANTIMICROBIAL RESISTANCE MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 27. NORTH AMERICA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 28. NORTH AMERICA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 29. NORTH AMERICA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 30. NORTH AMERICA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 31. NORTH AMERICA ANTIMICROBIAL RESISTANCE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 32. U.S. ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 33. U.S. ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 34. U.S. ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 35. U.S. ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 36. CANADA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 37. CANADA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 38. CANADA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 39. CANADA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 40. MEXICO ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 41. MEXICO ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 42. MEXICO ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 43. MEXICO ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 44. EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 45. EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 46. EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 47. EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 48. EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 49. GERMANY ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 50. GERMANY ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 51. GERMANY ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 52. GERMANY ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 53. FRANCE ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 54. FRANCE ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 55. FRANCE ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 56. FRANCE ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 57. UK ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 58. UK ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 59. UK ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 60. UK ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 61. ITALY ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 62. ITALY ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 63. ITALY ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 64. ITALY ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 65. SPAIN ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 66. SPAIN ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 67. SPAIN ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 68. SPAIN ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 69. REST OF EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 70. REST OF EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 71. REST OF EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 72. REST OF EUROPE ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 73. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 74. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 75. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 76. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 77. ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 78. JAPAN ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 79. JAPAN ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 80. JAPAN ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 81. JAPAN ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 82. CHINA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 83. CHINA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 84. CHINA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 85. CHINA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 86. INDIA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 87. INDIA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 88. INDIA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 89. INDIA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 90. AUSTRALIA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 91. AUSTRALIA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 92. AUSTRALIA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 93. AUSTRALIA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 94. SOUTH KOREA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 95. SOUTH KOREA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 96. SOUTH KOREA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 97. SOUTH KOREA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 98. REST OF ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 99. REST OF ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 100. REST OF ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 101. REST OF ASIA-PACIFIC ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 102. LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 103. LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 104. LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 105. LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 106. LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 107. BRAZIL ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 108. BRAZIL ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 109. BRAZIL ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 110. BRAZIL ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 111. SAUDI ARABIA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 112. SAUDI ARABIA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 113. SAUDI ARABIA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 114. SAUDI ARABIA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 115. SOUTH AFRICA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 116. SOUTH AFRICA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 117. SOUTH AFRICA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 118. SOUTH AFRICA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 119. REST OF LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 120. REST OF LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN, 2022-2032 ($MILLION)
TABLE 121. REST OF LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 122. REST OF LAMEA ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION, 2022-2032 ($MILLION)
TABLE 123. ALKEM LABORATORIES LTD.: KEY EXECUTIVES
TABLE 124. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 125. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS
TABLE 126. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 127. ALKEM LABORATORIES LTD.: KEY STRATERGIES
TABLE 128. PFIZER INC.: KEY EXECUTIVES
TABLE 129. PFIZER INC.: COMPANY SNAPSHOT
TABLE 130. PFIZER INC.: PRODUCT SEGMENTS
TABLE 131. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 132. PFIZER INC.: KEY STRATERGIES
TABLE 133. ACURX PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 134. ACURX PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 135. ACURX PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 136. ACURX PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 137. BASILEA PHARMACEUTICA LTD: KEY EXECUTIVES
TABLE 138. BASILEA PHARMACEUTICA LTD: COMPANY SNAPSHOT
TABLE 139. BASILEA PHARMACEUTICA LTD: PRODUCT SEGMENTS
TABLE 140. BASILEA PHARMACEUTICA LTD: PRODUCT PORTFOLIO
TABLE 141. CUMBERLAND PHARMACEUTICALS: KEY EXECUTIVES
TABLE 142. CUMBERLAND PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 143. CUMBERLAND PHARMACEUTICALS: PRODUCT SEGMENTS
TABLE 144. CUMBERLAND PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 145. CUMBERLAND PHARMACEUTICALS: KEY STRATERGIES
TABLE 146. WOCKHARDT LIMITED.: KEY EXECUTIVES
TABLE 147. WOCKHARDT LIMITED.: COMPANY SNAPSHOT
TABLE 148. WOCKHARDT LIMITED.: PRODUCT SEGMENTS
TABLE 149. WOCKHARDT LIMITED.: PRODUCT PORTFOLIO
TABLE 150. PARATEK PHARMACEUTICALS INC: KEY EXECUTIVES
TABLE 151. PARATEK PHARMACEUTICALS INC: COMPANY SNAPSHOT
TABLE 152. PARATEK PHARMACEUTICALS INC: PRODUCT SEGMENTS
TABLE 153. PARATEK PHARMACEUTICALS INC: PRODUCT PORTFOLIO
TABLE 154. NABRIVA THERAPEUTICS PLC: KEY EXECUTIVES
TABLE 155. NABRIVA THERAPEUTICS PLC: COMPANY SNAPSHOT
TABLE 156. NABRIVA THERAPEUTICS PLC: PRODUCT SEGMENTS
TABLE 157. NABRIVA THERAPEUTICS PLC: PRODUCT PORTFOLIO
TABLE 158. NABRIVA THERAPEUTICS PLC: KEY STRATERGIES
TABLE 159. INNOVIVA, INC: KEY EXECUTIVES
TABLE 160. INNOVIVA, INC: COMPANY SNAPSHOT
TABLE 161. INNOVIVA, INC: PRODUCT SEGMENTS
TABLE 162. INNOVIVA, INC: PRODUCT PORTFOLIO
TABLE 163. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 164. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 165. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 166. MERCK & CO., INC.: PRODUCT PORTFOLIO

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 抗菌薬耐性のグローバル市場（2023-2032）：併用療法、テトラサイクリン系薬剤、セファロスポリン系薬剤、糖ペプチド・脂肪糖ペプチド、オキサゾリジノン系薬剤、その他(Antimicrobial Resistance Market By Drug Class (Combination therapies, Tetracyclines, Cephalosporins, Glycopeptides and Lipoglycopeptides, Oxazolidinones, Others), By Pathogen (Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus Spp, Others), By Indication (Complicated Urinary Tract Infections (cUTI), Blood stream infections, Acute bacterial skin and skin structure infections (ABSSSI), Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP), Community acquired pneumonia (CAP), Others), By Mechanism of Action (Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 耳感染症治療のグローバル市場（2023-2032）：内耳、中耳、外耳

    • ◆H&Iグローバルリサーチのお客様（例）◆